CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
Esmolol administration +2 moredrug
Likely dose
Esmolol administration 50 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01431612
NCT01431612Phase 2Completed
CompareCT.gov

The Effects of ß1-receptor Blockade and α1-adrenergic Agonist on the Kinetics of Lactated Ringer's Solution During Surgery

Sodertalje Hospital·interventional·Posted Sep 9, 2011·Updated Sep 9, 2011

In Brief

A Phase 2 clinical trial evaluating Esmolol administration, Phenylephrine infusion, and 1 other intervention for Ovarian Cyst. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The aim this study was to examine to what degree the slow turnover of lactated Ringer's solution during anesthesia and surgery can be prevented by infusing esmolol (a ß1-receptor blocker) or phenylephrine in patients undergoing laparoscopic gynecological surgery performed under intravenous anesthesia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cyst
CountriesChina
CollaboratorsZhejiang University

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 9, 2011
Enrollment StartNov 1, 2008
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 14.8 years ago

Interventions

Esmolol administrationdrug

50 µg/kg/min of the ß1-receptor-blocker esmolol was infused intravenous over 3 hours

Phenylephrine infusiondrug

0.01 µg/kg/min of the alpha-1-adrenergic receptor agonist phenylephrine

Lactated Ringer´s solutiondrug

Intravenous Infusion of 10 ml/h lactated Ringer's solution that contained no drug